Brolucizumab for neovascular AMD: does it work? - Fast Papers #5
Автор: Oftalmo University
Загружено: 2024-09-30
Просмотров: 122
⚡️ Welcome to Fast Papers! ⚡️
👁️ Do you want us to talk about a specific topic or paper? Tell us in the comments and we will do it!
Hit subscribe to never miss an episode and stay ahead in the world of eye care!
📄 This episode Paper: "Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study"
🔗 Link: https://bjo.bmj.com/content/106/9/1288
The article “Short-term real-world outcomes following intravitreal administration of brolucizumab for neovascular AMD: the SHIFT study” explores the efficacy and safety of brolucizumab, a novel anti-VEGF agent, in the treatment of neovascular age-related macular degeneration (AMD). The study analyzed retrospective data from patients who had received brolucizumab after previous treatment with other anti-VEGF agents, and focused on assessing changes in visual acuity, retinal structure, and the occurrence of adverse events. The results of the study suggest that brolucizumab may represent a treatment option in patients with neovascular AMD who do not respond well to other anti-VEGF agents, although an increased rate of intraocular inflammation was observed. Larger studies are needed to determine the long-term efficacy and safety of brolucizumab in a routine clinical setting.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
